Everolimus-induced epithelial to mesenchymal transition (EMT) in bronchial/pulmonary cells: when the dosage does matter in transplantation
Journal article published in 2016 by
Paola Tomei,
Valentina Masola,
Simona Granata,
Pierluigi Carratù,
Miriam Ficial,
Gloria Bellin 
,
Valentina Anna Ventura,
Maurizio Onisto,
Onofrio Resta,
Giovanni Gambaro,
Marco Chilosi,
Antonio Lupo,
Gianluigi Zaza
,
Valentina Anna Ventura,
Maurizio Onisto,
Onofrio Resta,
Giovanni Gambaro,
Marco Chilosi,
Antonio Lupo,
Gianluigi Zaza
This paper is available in a repository.
Full text: Download
Published version:
archiving forbidden
Data provided by 
Abstract
Everolimus (EVE) is a mammalian target of rapamycin inhibitor (mTOR-I) widely used in transplantation that may determine some severe adverse events, including pulmonary fibrosis. The pathogenic mechanism of mTOR-I-associated pulmonary toxicity is still unclear, but epithelial to mesenchymal transition (EMT) of bronchial/pulmonary cells may play a role.